Mammography

Detect breast cancer earlier, with confidence

Transpara AI for breast cancer mammography has been evaluated in more than 50+ peer-reviewed studies and dozens conference presentations. All of the data on Transpara’s performance – and we have a lot of data – is public, published and readily available.

Transpara solutions work together to provide a clear, concise, and accurate assessment of each exam (your ‘second pair’ of eyes), helping you focus on the highest risk cases and triage patients toward the most appropriate supplemental screening modalities.

Importantly, the algorithm’s performance is strong when it matters most: Transpara Detection is accurate and robust regardless of a woman’s ethnicity, age, BMI, and breast density.

Transpara offers multiple use cases in breast cancer mammography:

Replace up to 80% of exams in first reading with Transpara for time saving
Detection support for difficult cancers to support a higher detection rate, also of small cancer
Detection support for dense breast
Detection support for 2D and 3D, screening and diagnostic mammography
Automatic density assessment
Automatic comparison with priors

We have implemented Transpara AI in large scale operational screening programs in the Nordics, with documented outcomes for efficiency and patient outcome.

Increased detection rate
Reduced false positive rate
Reduced unnecessary recall
Reduced workload with more than 35%

All documented in published clinical evidence: Link

About ScreenPoint

Screepoint Medical is working with breast clinicians to continually improve the clinically proven deep learning algorithms in Transpara®. We are committed to further improve accuracy, consistency and reduce unnecessary recalls, a common cause of anxiety for women undergoing mammography.

ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, world leading experts in quantitative breast image analysis and computer aided detection.

The resulting product, Transpara, has featured in multiple peer-reviewed publications that show it enables significant clinical improvements to the timely diagnosis of breast cancer.

Detect breast cancer earlier, with confidence

About ScreenPoint

Get in contact

Frederik Baastrup Hammer

Ulrik Juul Rokkedal Therkildsen

Martin Frandsen

Anders Bille